Jones Thomas L, Neville Daniel M, Chauhan Anoop J
Department of Research & Innovation, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Ther Deliv. 2018 Feb 1;9(3):169-176. doi: 10.4155/tde-2017-0103.
Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients' ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.
哮喘和慢性阻塞性肺疾病主要通过吸入药物进行治疗,但将药物输送到其作用部位存在问题;患者使用吸入器的能力会影响治疗反应。有多种吸入器设备可供使用,但它们的易用性各不相同,从而对依从性产生有意或无意的影响。Ellipta设备是一种新型泡罩条干粉吸入器,具有中等阻力,在一系列吸气流量下能提供一致的输送剂量。经证实,Ellipta易于使用,在多项评估中与其他吸入器设备相比更受患者青睐。Ellipta用于施用多种吸入药物,均采用每日单剂量方案,这使其成为难以遵循复杂吸入治疗方案的患者的理想选择。